It has been reported that the use of glucagon-like peptide-1 receptor agonists (GLP-RA) reduced the risk of stroke [57, 58], and therefore the significantly higher proportion of GLP1-RA comediation in the empagliflozin group might have contributed to the lower risk of stroke. This evidence concerns the gene GLP1R and stroke disorder.